首页 > 最新文献

Journal of Critical Care Medicine最新文献

英文 中文
Successful Extracorporeal Blood Purification Therapy using Double Haemoadsorption Device in Severe Endotoxin Septic Shock: A Case Report. 双重血液吸附装置体外血液净化治疗严重内毒素感染性休克1例。
IF 1.1 Pub Date : 2022-10-01 DOI: 10.2478/jccm-2022-0028
Stefano Ferraro, Stefania Bianzina, Sonila Mocka, Francesca Cappadona, Giovanni Battista Traverso, Fabio Massarino, Pasquale Esposito

Introduction: In patients admitted to the Intensive Care Unit (ICU), sepsis can lead to acute kidney injury (AKI), which may require the initiation of continuous renal replacement therapy (CRRT) in 15-20% of cases. There is no consensus about the best extracorporeal treatment to choose in septic patients with AKI.

Case presentation: We describe the case of a 70-year-old woman admitted to the ICU with a severe endotoxin septic shock due to Neisseria meningitidis serogroup C. Despite prompt medical intervention, including fluid resuscitation, high dose vasopressor, inotrope support, and broad-spectrum antimicrobial treatment, in a few hours patient's haemodynamic worsened and she developed multi-organ failure, including severe AKI, requiring CRRT. So, continuous veno-venous haemodiafiltration was started, using an oXiris® haemodiafilter set, in series with an adsorber device (CytoSorb®). After 48 hours of this combined extracorporeal treatment, haemodynamic parameters improved, allowing a significant reduction of the vasoactive therapy, with a concomitant decrease in endotoxin and inflammatory markers serum levels. In the following days patient's conditions still improved and renal function recovered.

Conclusions: Timely extracorporeal blood purification therapy, using a double haemoadsorption device, may be effective in the management of severe septic shock.

在入住重症监护病房(ICU)的患者中,败血症可导致急性肾损伤(AKI),这可能需要在15-20%的病例中开始持续肾替代治疗(CRRT)。对于脓毒症AKI患者的最佳体外治疗选择尚无共识。病例介绍:我们描述了一例70岁女性因脑膜炎奈瑟菌c血清组引起的严重内毒素感染性休克入住ICU的病例。尽管及时的医疗干预,包括液体复苏、大剂量血管加压剂、肌力支持和广谱抗菌药物治疗,在几个小时内,患者的血流动力学恶化,并发展为多器官衰竭,包括严重的AKI,需要CRRT。因此,开始使用oXiris®血液滤过器,与吸附装置(CytoSorb®)串联进行连续的静脉-静脉血液滤过。这种体外联合治疗48小时后,血流动力学参数得到改善,血管活性治疗显著减少,内毒素和炎症标志物血清水平也随之下降。在接下来的几天里,病人的情况仍然改善,肾功能恢复。结论:及时采用体外血液净化治疗,采用双血吸附装置,可有效治疗重症感染性休克。
{"title":"Successful Extracorporeal Blood Purification Therapy using Double Haemoadsorption Device in Severe Endotoxin Septic Shock: A Case Report.","authors":"Stefano Ferraro,&nbsp;Stefania Bianzina,&nbsp;Sonila Mocka,&nbsp;Francesca Cappadona,&nbsp;Giovanni Battista Traverso,&nbsp;Fabio Massarino,&nbsp;Pasquale Esposito","doi":"10.2478/jccm-2022-0028","DOIUrl":"https://doi.org/10.2478/jccm-2022-0028","url":null,"abstract":"<p><strong>Introduction: </strong>In patients admitted to the Intensive Care Unit (ICU), sepsis can lead to acute kidney injury (AKI), which may require the initiation of continuous renal replacement therapy (CRRT) in 15-20% of cases. There is no consensus about the best extracorporeal treatment to choose in septic patients with AKI.</p><p><strong>Case presentation: </strong>We describe the case of a 70-year-old woman admitted to the ICU with a severe endotoxin septic shock due to Neisseria meningitidis serogroup C. Despite prompt medical intervention, including fluid resuscitation, high dose vasopressor, inotrope support, and broad-spectrum antimicrobial treatment, in a few hours patient's haemodynamic worsened and she developed multi-organ failure, including severe AKI, requiring CRRT. So, continuous veno-venous haemodiafiltration was started, using an oXiris® haemodiafilter set, in series with an adsorber device (CytoSorb®). After 48 hours of this combined extracorporeal treatment, haemodynamic parameters improved, allowing a significant reduction of the vasoactive therapy, with a concomitant decrease in endotoxin and inflammatory markers serum levels. In the following days patient's conditions still improved and renal function recovered.</p><p><strong>Conclusions: </strong>Timely extracorporeal blood purification therapy, using a double haemoadsorption device, may be effective in the management of severe septic shock.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In between Opioid Crisis and the Need to Treat Pain, where do we Stand? 在阿片类药物危机和治疗疼痛的需要之间,我们站在哪里?
IF 1.1 Pub Date : 2022-10-01 DOI: 10.2478/jccm-2022-0029
Daniela Ionescu, Simona Margarit
{"title":"In between Opioid Crisis and the Need to Treat Pain, where do we Stand?","authors":"Daniela Ionescu,&nbsp;Simona Margarit","doi":"10.2478/jccm-2022-0029","DOIUrl":"https://doi.org/10.2478/jccm-2022-0029","url":null,"abstract":"","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Family Burden of ICU Survivors and Correlations with Patient Quality of Life and Psychometric Scores - A Pilot Study. ICU幸存者的家庭负担与患者生活质量和心理测量评分的相关性——一项初步研究。
IF 1.1 Pub Date : 2022-10-01 DOI: 10.2478/jccm-2022-0027
Vassiliki Mantziou, Charikleia S Vrettou, Alice G Vassiliou, Stylianos E Orfanos, Anastasia Kotanidou, Ioanna Dimopoulou

Introduction: Post intensive care syndrome (PICS) affects an increasing number of critical illness survivors and their families, with serious physical and psychological sequelae. Since little is known about the burden of critical illness on ICU survivor families, we conducted a prospective observational study aiming to assess this, and investigate correlations of the patients' psychometric and health-related quality of life (HRQOL) scores with family burden.

Materials and methods: Twenty-nine patients were evaluated in the presence of a family member. Participants were assessed with the use of validated scales for anxiety, depression, post-traumatic stress disorder, cognitive decline, and the family burden scale (FBS).

Results: High burden was present in 27.6% of family members. Statistically significant correlations were observed between the FBS score and trait anxiety, depression, and the physical and psychological components of HRQOL.

Conclusions: Our results suggest that family burden following critical illness is common, suggesting that its assessment should be incorporated in the evaluation of PICS-family in large observational studies.

重症监护后综合征(PICS)影响到越来越多的危重疾病幸存者及其家属,并带来严重的生理和心理后遗症。由于对重症监护室幸存者家庭的危重疾病负担知之甚少,我们进行了一项前瞻性观察研究,旨在评估这一点,并探讨患者心理测量和健康相关生活质量(HRQOL)评分与家庭负担的相关性。材料和方法:29例患者在家属在场的情况下进行评估。使用焦虑、抑郁、创伤后应激障碍、认知衰退和家庭负担量表(FBS)对参与者进行评估。结果:27.6%的家庭成员存在高负担。FBS评分与特质焦虑、抑郁以及HRQOL的生理和心理成分之间存在显著的统计学相关性。结论:我们的研究结果表明,危重疾病后的家庭负担是常见的,这表明在大型观察性研究中,应将其评估纳入对pics家庭的评估。
{"title":"Family Burden of ICU Survivors and Correlations with Patient Quality of Life and Psychometric Scores - A Pilot Study.","authors":"Vassiliki Mantziou,&nbsp;Charikleia S Vrettou,&nbsp;Alice G Vassiliou,&nbsp;Stylianos E Orfanos,&nbsp;Anastasia Kotanidou,&nbsp;Ioanna Dimopoulou","doi":"10.2478/jccm-2022-0027","DOIUrl":"https://doi.org/10.2478/jccm-2022-0027","url":null,"abstract":"<p><strong>Introduction: </strong>Post intensive care syndrome (PICS) affects an increasing number of critical illness survivors and their families, with serious physical and psychological sequelae. Since little is known about the burden of critical illness on ICU survivor families, we conducted a prospective observational study aiming to assess this, and investigate correlations of the patients' psychometric and health-related quality of life (HRQOL) scores with family burden.</p><p><strong>Materials and methods: </strong>Twenty-nine patients were evaluated in the presence of a family member. Participants were assessed with the use of validated scales for anxiety, depression, post-traumatic stress disorder, cognitive decline, and the family burden scale (FBS).</p><p><strong>Results: </strong>High burden was present in 27.6% of family members. Statistically significant correlations were observed between the FBS score and trait anxiety, depression, and the physical and psychological components of HRQOL.</p><p><strong>Conclusions: </strong>Our results suggest that family burden following critical illness is common, suggesting that its assessment should be incorporated in the evaluation of PICS-family in large observational studies.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings. 在现实生活中,非试验环境中类固醇处方对COVID-19相关肺炎的可变性
IF 1.1 Pub Date : 2022-10-01 DOI: 10.2478/jccm-2022-0025
Rashid Nadeem, Islam Bon, Doaa Algohary, Mohd Kafeel Khan, Nilesh Gundawar, Mohammed Abdullah, Ekta Sharma, Moatz Galal Elzeiny, Mayada Mahmoud, Ashraf Elhoufi, Yusra Omar Alshaikh Sayed Ahmed, Gloria Gheno, Maged Talaat Salama Khalil, Tamseela Hussain

The RECOVERY study documented lower 28-day mortality with the use of dexamethasone in hospitalized patients on invasive mechanical ventilation or oxygen with COVID-19 Pneumonia. We aimed to examine the practice patterns of steroids use, and their impact on mortality and length of stay in ICU. We retrospectively examined records of all patients with confirmed Covid 19 pneumonia admitted to the ICU of Dubai hospital from January 1st, 2020 - June 30th, 2020. We assigned patients to four groups (No steroids, low dose, medium dose, and high dose steroids). The primary clinical variable of interest was doses of steroids. Secondary outcomes were 28-day mortality and length of stay in ICU". We found variability in doses of steroid treatment. The most frequently used dose was the high dose. Patients who survived were on significantly higher doses of steroids and had significantly longer stays in ICU. The prescription of steroids in Covid-19 ARDS is variable. The dose of steroids impacts mortality rate and length of stay in ICU, although patients treated with high dose steroids seem to stay more days in ICU.

康复研究表明,在有创机械通气或吸氧的COVID-19肺炎住院患者中,使用地塞米松可降低28天死亡率。我们的目的是检查类固醇使用的实践模式,及其对死亡率和ICU住院时间的影响。我们回顾性分析了2020年1月1日至2020年6月30日在迪拜医院ICU收治的所有确诊Covid - 19肺炎患者的记录。我们将患者分为四组(无类固醇、低剂量、中剂量和高剂量类固醇)。主要的临床变量是类固醇的剂量。次要结局为28天死亡率和ICU住院时间。我们发现类固醇治疗剂量存在差异。最常用的剂量是高剂量。存活下来的患者服用的类固醇剂量明显更高,在ICU的住院时间也明显更长。Covid-19急性呼吸窘迫综合征的类固醇处方是可变的。类固醇的剂量影响死亡率和在ICU的住院时间,尽管接受高剂量类固醇治疗的患者似乎在ICU呆的时间更长。
{"title":"Variability of Steroid Prescription for COVID-19 Associated Pneumonia in Real-Life, Non-Trial Settings.","authors":"Rashid Nadeem,&nbsp;Islam Bon,&nbsp;Doaa Algohary,&nbsp;Mohd Kafeel Khan,&nbsp;Nilesh Gundawar,&nbsp;Mohammed Abdullah,&nbsp;Ekta Sharma,&nbsp;Moatz Galal Elzeiny,&nbsp;Mayada Mahmoud,&nbsp;Ashraf Elhoufi,&nbsp;Yusra Omar Alshaikh Sayed Ahmed,&nbsp;Gloria Gheno,&nbsp;Maged Talaat Salama Khalil,&nbsp;Tamseela Hussain","doi":"10.2478/jccm-2022-0025","DOIUrl":"https://doi.org/10.2478/jccm-2022-0025","url":null,"abstract":"<p><p>The RECOVERY study documented lower 28-day mortality with the use of dexamethasone in hospitalized patients on invasive mechanical ventilation or oxygen with COVID-19 Pneumonia. We aimed to examine the practice patterns of steroids use, and their impact on mortality and length of stay in ICU. We retrospectively examined records of all patients with confirmed Covid 19 pneumonia admitted to the ICU of Dubai hospital from January 1st, 2020 - June 30th, 2020. We assigned patients to four groups (No steroids, low dose, medium dose, and high dose steroids). The primary clinical variable of interest was doses of steroids. Secondary outcomes were 28-day mortality and length of stay in ICU\". We found variability in doses of steroid treatment. The most frequently used dose was the high dose. Patients who survived were on significantly higher doses of steroids and had significantly longer stays in ICU. The prescription of steroids in Covid-19 ARDS is variable. The dose of steroids impacts mortality rate and length of stay in ICU, although patients treated with high dose steroids seem to stay more days in ICU.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation. 替柯planin在2019冠状病毒感染患者静脉-静脉体外膜氧合中的药代动力学
IF 1.1 Pub Date : 2022-10-01 DOI: 10.2478/jccm-2022-0021
Nobuhisa Hirayu, Atsuo Nakamura, Toshio Morita, Osamu Takasu

Introduction: Patients with severe coronavirus disease 2019 (COVID-19) receiving ventilation or pulmonary support via veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be infected with drug-resistant bacteria. When introducing VV-ECMO, the changes in serum antibiotic concentration should be considered due to an increased volume of distribution (Vd). However, no pharmacokinetic study has assessed teicoplanin (TEIC) treatment in patients with COVID-19 receiving VV-ECMO.

Case presentation: A 71-year-old man diagnosed with COVID-19 visited a primary hospital. His oxygenation conditions worsened despite treatment with favipiravir and methylprednisolone as well as oxygen therapy. After his transfer to our center, tracheal intubation and steroid pulse therapy were initiated. Seven days after admission, VV-ECMO was performed. TEIC was administered for secondary bacterial infection. The serum TEIC concentration remained within the therapeutic range, indicating that VV-ECMO did not significantly affect TEIC pharmacokinetics. VV-ECMO was discontinued 17 days after admission. However, he developed multi-organ disorder and died 42 days after admission.

Conclusion: As TEIC prevents viral invasion, it may be used with ECMO in patients with COVID-19 requiring ventilation; however, the altered pharmacokinetics of TEIC, such as increased Vd, should be considered. Therefore, TEIC pharmacokinetics in VV-ECMO should be assessed in future studies with an appropriate number of patients.

重症冠状病毒病2019 (COVID-19)患者通过静脉-静脉体外膜氧合(VV-ECMO)进行通气或肺支持,可能会感染耐药菌。当引入VV-ECMO时,应考虑由于分布容积(Vd)增加而引起的血清抗生素浓度的变化。然而,没有药代动力学研究评估teicoplanin (TEIC)在接受VV-ECMO的COVID-19患者中的治疗效果。病例介绍:一名确诊为COVID-19的71岁男子到基层医院就诊。尽管给予法匹拉韦和甲基强的松龙以及氧气治疗,他的氧合情况仍恶化。他转到我中心后,气管插管和类固醇脉冲治疗开始。入院后第7天行VV-ECMO。继发性细菌感染给予TEIC。血清TEIC浓度保持在治疗范围内,表明VV-ECMO对TEIC药代动力学没有显著影响。入院后17天停止VV-ECMO。然而,他出现了多器官疾病,并在入院42天后死亡。结论:TEIC可预防病毒侵袭,可与ECMO联合应用于需要通气的COVID-19患者;然而,应考虑TEIC药代动力学的改变,如Vd升高。因此,TEIC在VV-ECMO中的药代动力学应在未来的研究中进行评估,纳入适当数量的患者。
{"title":"Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation.","authors":"Nobuhisa Hirayu,&nbsp;Atsuo Nakamura,&nbsp;Toshio Morita,&nbsp;Osamu Takasu","doi":"10.2478/jccm-2022-0021","DOIUrl":"https://doi.org/10.2478/jccm-2022-0021","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with severe coronavirus disease 2019 (COVID-19) receiving ventilation or pulmonary support via veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be infected with drug-resistant bacteria. When introducing VV-ECMO, the changes in serum antibiotic concentration should be considered due to an increased volume of distribution (Vd). However, no pharmacokinetic study has assessed teicoplanin (TEIC) treatment in patients with COVID-19 receiving VV-ECMO.</p><p><strong>Case presentation: </strong>A 71-year-old man diagnosed with COVID-19 visited a primary hospital. His oxygenation conditions worsened despite treatment with favipiravir and methylprednisolone as well as oxygen therapy. After his transfer to our center, tracheal intubation and steroid pulse therapy were initiated. Seven days after admission, VV-ECMO was performed. TEIC was administered for secondary bacterial infection. The serum TEIC concentration remained within the therapeutic range, indicating that VV-ECMO did not significantly affect TEIC pharmacokinetics. VV-ECMO was discontinued 17 days after admission. However, he developed multi-organ disorder and died 42 days after admission.</p><p><strong>Conclusion: </strong>As TEIC prevents viral invasion, it may be used with ECMO in patients with COVID-19 requiring ventilation; however, the altered pharmacokinetics of TEIC, such as increased Vd, should be considered. Therefore, TEIC pharmacokinetics in VV-ECMO should be assessed in future studies with an appropriate number of patients.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Lethal Caffeine Overdose with Haemodialysis: A Case Report and Review. 血液透析治疗致死性咖啡因过量:一例报告和回顾。
IF 1.1 Pub Date : 2022-10-01 DOI: 10.2478/jccm-2022-0019
Christian C Toquica Gahona, Ashwin Kodagnur Bharadwaj, Monarch Shah, Umesh Bhagat, Paul Sterman, William Vasquez

Caffeine, chemically 1,3,7-trimethylxanthine, is the most widely consumed central nervous system stimulant in the world with pleiotropic effects on the cardiovascular, pulmonary, and renal systems. The advent of over the counter (OTC) caffeine formulations has opened the window for potential toxicity, either by inadvertent or intentional overdosing. We present the case of a patient who attempted suicide by caffeine overdose treated with emergent haemodialysis and a review of the literature.

咖啡因,化学性质为1,3,7-三甲基黄嘌呤,是世界上最广泛使用的中枢神经系统兴奋剂,对心血管、肺和肾系统具有多效性作用。非处方(OTC)咖啡因配方的出现打开了潜在毒性的窗口,无论是无意的还是有意的过量服用。我们提出的情况下,病人试图自杀咖啡因过量与紧急血液透析治疗和文献综述。
{"title":"Treatment of Lethal Caffeine Overdose with Haemodialysis: A Case Report and Review.","authors":"Christian C Toquica Gahona,&nbsp;Ashwin Kodagnur Bharadwaj,&nbsp;Monarch Shah,&nbsp;Umesh Bhagat,&nbsp;Paul Sterman,&nbsp;William Vasquez","doi":"10.2478/jccm-2022-0019","DOIUrl":"https://doi.org/10.2478/jccm-2022-0019","url":null,"abstract":"<p><p>Caffeine, chemically 1,3,7-trimethylxanthine, is the most widely consumed central nervous system stimulant in the world with pleiotropic effects on the cardiovascular, pulmonary, and renal systems. The advent of over the counter (OTC) caffeine formulations has opened the window for potential toxicity, either by inadvertent or intentional overdosing. We present the case of a patient who attempted suicide by caffeine overdose treated with emergent haemodialysis and a review of the literature.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effective Outcome of HBOT as an Adjuvant Therapy in Patients Diagnosed with COVID-19 in a Tertiary Care Hospital - A Preliminary Study. HBOT作为辅助治疗在三级医院诊断为COVID-19的患者的有效结果的初步研究
IF 1.1 Pub Date : 2022-08-12 eCollection Date: 2022-07-01 DOI: 10.2478/jccm-2022-0008
Thiruppathy Palaniappan, Asif Shaikh, Navamani Kirthika

Introduction: Hyperbaricoxygen therapy (HBOT) is breathing100% oxygen in pressurised chamber. This therapy ensures quick oxygen delivery to the bloodstream. In patients with severe COVID-19 pneumonia, progressive hypoxemia occurs. Oxygen therapy hasa significant role in its management.

Aim of the study: The objective was to study the efficacy of hyperbaric oxygen therapy (HBOT) as adjuvant therapy for reducing the requirement of additional oxygen supplementationin patients with moderate to severe ARDS diagnosed with COVID-19.

Methods: A single-centre prospective pilot cohort study was conducted ata tertiary care hospital from December 2020 to February 2021 over two months. Fifty patients with COVID-19 needingoxygen, satisfying the selection criteria, were included. Hyperbaricoxygen therapy wasgiven to all patients. The patient received30-45 minutes of hyperbaric oxygen with 15 minutes of pressurizing and depressurizing at 2.0 atmosphere absolute (ATA) with or without airbrakesas per the critical care team. Oxygen requirement, PaO2, andcondition at discharge were considered as primary outcome variables.

Results: Among the 50 participants studied, the mean age was 53.64±13.26 years. Out of 50 participants, 49(98.00%) had PaO2≤80 mmHg, and one (2.00%) had >80 PaO2. All the participants 50(100%) had PaO2 as 90 mmHg after three sittings.

Conclusion: This studyshows promising results in using HBOT to overcome respiratory failure in COVID-19. HBOT reduced the need for oxygen by improving the oxygen saturation levels.

简介:高压氧疗法(HBOT)是在加压室内呼吸100%氧气。这种疗法可以确保血液中氧气的快速输送。重症COVID-19肺炎患者会出现进行性低氧血症。氧疗在其治疗中起着重要作用。研究目的:目的是研究高压氧治疗(HBOT)作为辅助治疗减少诊断为COVID-19的中重度ARDS患者额外补氧需求的疗效。方法:从2020年12月至2021年2月,在一家三级医院进行了一项为期两个月的单中心前瞻性试点队列研究。入选符合入选标准的新冠肺炎患者50例。所有患者均给予高压氧治疗。根据重症监护小组的要求,患者接受30-45分钟的高压氧治疗,并在绝对大气压2.0 (ATA)下进行15分钟的加压和减压,有或没有空气制动。需氧量、PaO2和出院时的状况被认为是主要的结局变量。结果:50例患者平均年龄为53.64±13.26岁。50名参与者中,49名(98.00%)PaO2≤80mmhg, 1名(2.00%)PaO2 > 80mmhg。三次静坐后,所有参与者(100%)的PaO2均为90 mmHg。结论:本研究显示HBOT治疗新冠肺炎患者呼吸衰竭有良好效果。HBOT通过提高氧饱和度来减少对氧气的需求。
{"title":"Effective Outcome of HBOT as an Adjuvant Therapy in Patients Diagnosed with COVID-19 in a Tertiary Care Hospital - A Preliminary Study.","authors":"Thiruppathy Palaniappan,&nbsp;Asif Shaikh,&nbsp;Navamani Kirthika","doi":"10.2478/jccm-2022-0008","DOIUrl":"https://doi.org/10.2478/jccm-2022-0008","url":null,"abstract":"<p><strong>Introduction: </strong>Hyperbaricoxygen therapy (HBOT) is breathing100% oxygen in pressurised chamber. This therapy ensures quick oxygen delivery to the bloodstream. In patients with severe COVID-19 pneumonia, progressive hypoxemia occurs. Oxygen therapy hasa significant role in its management.</p><p><strong>Aim of the study: </strong>The objective was to study the efficacy of hyperbaric oxygen therapy (HBOT) as adjuvant therapy for reducing the requirement of additional oxygen supplementationin patients with moderate to severe ARDS diagnosed with COVID-19.</p><p><strong>Methods: </strong>A single-centre prospective pilot cohort study was conducted ata tertiary care hospital from December 2020 to February 2021 over two months. Fifty patients with COVID-19 needingoxygen, satisfying the selection criteria, were included. Hyperbaricoxygen therapy wasgiven to all patients. The patient received30-45 minutes of hyperbaric oxygen with 15 minutes of pressurizing and depressurizing at 2.0 atmosphere absolute (ATA) with or without airbrakesas per the critical care team. Oxygen requirement, PaO2, andcondition at discharge were considered as primary outcome variables.</p><p><strong>Results: </strong>Among the 50 participants studied, the mean age was 53.64±13.26 years. Out of 50 participants, 49(98.00%) had PaO2≤80 mmHg, and one (2.00%) had >80 PaO2. All the participants 50(100%) had PaO2 as 90 mmHg after three sittings.</p><p><strong>Conclusion: </strong>This studyshows promising results in using HBOT to overcome respiratory failure in COVID-19. HBOT reduced the need for oxygen by improving the oxygen saturation levels.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40349986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The Use of Metaraminol as a Vasopressor in Critically Unwell Patients: A Narrative Review and a Survey of UK Practice. 在危重病人中使用甲氨醇作为血管加压剂:一个叙述性的回顾和英国实践的调查。
IF 1.1 Pub Date : 2022-08-12 eCollection Date: 2022-07-01 DOI: 10.2478/jccm-2022-0017
Lina Grauslyte, Nathalie Bolding, Mandeep Phull, Tomas Jovaisa

Background: Major international guidelines state that norepinephrine should be used as the first-line vasopressor to achieve adequate blood pressure in patients with hypotension or shock. However, recent observational studies report that in the United Kingdom and Australia, metaraminol is often used as second line medication for cardiovascular support.

Aim of the study: The aim of this study was to carry out a systematic review of metaraminol use for management of shock in critically unwell patients and carry out a survey evaluating whether UK critical care units use metaraminol and under which circumstances.

Methods: A systematic review literature search was conducted. A short telephone survey consisting of 6 questions regarding metaraminol use was conducted across 30 UK critical care units which included a mix of tertiary and district general intensive care units.

Results: Twenty-six of thirty contacted centres responded to our survey. Metaraminol was used in 88% of them in various settings and circumstances (emergency department, theatres, medical emergencies on medical wards), with 67% reporting use of metaraminol infusions in the critical care setting. The systematic literature review revealed several case reports and only two studies conducted in the last 20 years investigating the effect of metaraminol as a stand-alone vasopressor. Both studies focused on different aspects of metaraminol use and the data was incomparable, hence we decided not to perform a meta-analysis.

Conclusions: Metaraminol is widely used as a vasopressor inside and outside of the critical care setting in the UK despite limited evidence supporting its safety and efficacy for treating shock. Further service evaluation, observational studies and prospective randomised controlled trials are warranted to validate the role and safety profile of metaraminol in the treatment of the critically unwell patient.

背景:主要的国际指南指出,在低血压或休克患者中,应将去甲肾上腺素作为一线血管加压药物来达到适当的血压。然而,最近的观察性研究报告称,在英国和澳大利亚,甲氨醇经常被用作心血管支持的二线药物。研究目的:本研究的目的是对重症患者休克治疗中使用甲氨醇进行系统回顾,并开展一项调查,评估英国重症监护病房是否使用甲氨醇以及在何种情况下使用。方法:进行系统回顾文献检索。一项简短的电话调查包括6个问题,涉及到30个英国重症监护病房,其中包括三级和地区普通重症监护病房。结果:30个联系中心中有26个回应了我们的调查。其中88%的人在各种环境和情况下(急诊科、手术室、医疗病房的医疗紧急情况)使用了甲氨醇,67%的人报告在重症监护环境中使用了甲氨醇输注。系统的文献回顾显示,在过去的20年里,有几个病例报告和只有两个研究调查了甲氨醇作为一种独立的血管加压剂的作用。这两项研究都侧重于甲氨酚使用的不同方面,数据无法比较,因此我们决定不进行荟萃分析。结论:在英国,尽管支持其治疗休克的安全性和有效性的证据有限,但在重症监护环境内外,甲氨醇被广泛用作血管加压剂。需要进一步的服务评估、观察性研究和前瞻性随机对照试验来验证甲氨醇在治疗重症患者中的作用和安全性。
{"title":"The Use of Metaraminol as a Vasopressor in Critically Unwell Patients: A Narrative Review and a Survey of UK Practice.","authors":"Lina Grauslyte,&nbsp;Nathalie Bolding,&nbsp;Mandeep Phull,&nbsp;Tomas Jovaisa","doi":"10.2478/jccm-2022-0017","DOIUrl":"https://doi.org/10.2478/jccm-2022-0017","url":null,"abstract":"<p><strong>Background: </strong>Major international guidelines state that norepinephrine should be used as the first-line vasopressor to achieve adequate blood pressure in patients with hypotension or shock. However, recent observational studies report that in the United Kingdom and Australia, metaraminol is often used as second line medication for cardiovascular support.</p><p><strong>Aim of the study: </strong>The aim of this study was to carry out a systematic review of metaraminol use for management of shock in critically unwell patients and carry out a survey evaluating whether UK critical care units use metaraminol and under which circumstances.</p><p><strong>Methods: </strong>A systematic review literature search was conducted. A short telephone survey consisting of 6 questions regarding metaraminol use was conducted across 30 UK critical care units which included a mix of tertiary and district general intensive care units.</p><p><strong>Results: </strong>Twenty-six of thirty contacted centres responded to our survey. Metaraminol was used in 88% of them in various settings and circumstances (emergency department, theatres, medical emergencies on medical wards), with 67% reporting use of metaraminol infusions in the critical care setting. The systematic literature review revealed several case reports and only two studies conducted in the last 20 years investigating the effect of metaraminol as a stand-alone vasopressor. Both studies focused on different aspects of metaraminol use and the data was incomparable, hence we decided not to perform a meta-analysis.</p><p><strong>Conclusions: </strong>Metaraminol is widely used as a vasopressor inside and outside of the critical care setting in the UK despite limited evidence supporting its safety and efficacy for treating shock. Further service evaluation, observational studies and prospective randomised controlled trials are warranted to validate the role and safety profile of metaraminol in the treatment of the critically unwell patient.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40347790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Right Heart Failure as an Atypical Presentation of Chronic Type a Aortic Dissection - Multimodality Imaging for Accurate Diagnosis and Treatment. A Case Report and Mini-review of Literature. 右心衰作为慢性a型主动脉夹层的不典型表现——多模态影像准确诊断和治疗。一例病例报告及文献综述。
IF 1.1 Pub Date : 2022-08-12 eCollection Date: 2022-07-01 DOI: 10.2478/jccm-2022-0016
Ioan Tilea, Robert Adrian Dumbrava, Alexandra Mihaela Ratiu, Marius Mihai Harpa, Cosmin Marian Banceu, Dorina Nastasia Petra, Horatiu Suciu

Background: An intrapericardial organized haematoma secondary to chronic type A aortic dissection is an extremely rare cause of right heart failure. Imaging studies are essential in recognising and diagnosis of this distinctive medical condition and guiding the anticipated treatment.

Case presentation: A 70-year-old male patient was admitted for progressive symptoms of right heart failure. His cardiovascular history exposed an aortic valve replacement 22 years before with a Medtronic Hall 23 tilting valve with no regular follow-up. Classical signs of congestion were recognized at physical examination. Transthoracic two-dimensional echocardiography and thoraco-abdominal computed tomography angiography, as essential parts of multimodality imaging algorithm, established the underlying cause of right heart failure. Under total cardiopulmonary bypass and cardiac arrest, surgical removal of the haematoma and proximal repair of the ascending aorta with a patient-matched vascular graft were successfully performed. The patient was discharged in good condition with appropriate pharmacological treatment, guideline-directed; no imagistic signs of acute post-surgery complications were ascertained.

Conclusion: This paper highlights the importance of recognizing and providing a timely clinical and imagistic diagnosis of this very rare, potentially avoidable cause of right heart failure in patients with previous cardiac surgery.

背景:慢性A型主动脉夹层继发心包内有组织血肿是一种极为罕见的右心衰病因。影像学研究在识别和诊断这种特殊的医疗状况和指导预期的治疗是必不可少的。病例介绍:一名70岁男性患者因右心衰进行性症状入院。他的心血管病史显示22年前使用美敦力Hall 23倾斜瓣膜进行主动脉瓣置换术,没有定期随访。典型的充血症状是在体检时发现的。经胸二维超声心动图和胸腹计算机断层血管造影作为多模态成像算法的重要组成部分,确定了右心衰的根本原因。在完全体外循环和心脏骤停的情况下,我们成功地进行了血肿切除和升主动脉近端修复手术,并采用患者匹配的血管移植物。患者出院时情况良好,在指导下进行了适当的药物治疗;未发现急性术后并发症的影像学征象。结论:本文强调了认识和提供及时的临床和影像学诊断的重要性,这种非常罕见的,潜在的可避免的原因右心衰的患者既往心脏手术。
{"title":"Right Heart Failure as an Atypical Presentation of Chronic Type a Aortic Dissection - Multimodality Imaging for Accurate Diagnosis and Treatment. A Case Report and Mini-review of Literature.","authors":"Ioan Tilea,&nbsp;Robert Adrian Dumbrava,&nbsp;Alexandra Mihaela Ratiu,&nbsp;Marius Mihai Harpa,&nbsp;Cosmin Marian Banceu,&nbsp;Dorina Nastasia Petra,&nbsp;Horatiu Suciu","doi":"10.2478/jccm-2022-0016","DOIUrl":"https://doi.org/10.2478/jccm-2022-0016","url":null,"abstract":"<p><strong>Background: </strong>An intrapericardial organized haematoma secondary to chronic type A aortic dissection is an extremely rare cause of right heart failure. Imaging studies are essential in recognising and diagnosis of this distinctive medical condition and guiding the anticipated treatment.</p><p><strong>Case presentation: </strong>A 70-year-old male patient was admitted for progressive symptoms of right heart failure. His cardiovascular history exposed an aortic valve replacement 22 years before with a Medtronic Hall 23 tilting valve with no regular follow-up. Classical signs of congestion were recognized at physical examination. Transthoracic two-dimensional echocardiography and thoraco-abdominal computed tomography angiography, as essential parts of multimodality imaging algorithm, established the underlying cause of right heart failure. Under total cardiopulmonary bypass and cardiac arrest, surgical removal of the haematoma and proximal repair of the ascending aorta with a patient-matched vascular graft were successfully performed. The patient was discharged in good condition with appropriate pharmacological treatment, guideline-directed; no imagistic signs of acute post-surgery complications were ascertained.</p><p><strong>Conclusion: </strong>This paper highlights the importance of recognizing and providing a timely clinical and imagistic diagnosis of this very rare, potentially avoidable cause of right heart failure in patients with previous cardiac surgery.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40347785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized Physiological Medicine as the Future of Intensive Care Medicine. 个性化生理医学是重症监护医学的未来。
IF 1.1 Pub Date : 2022-08-12 eCollection Date: 2022-07-01 DOI: 10.2478/jccm-2022-0020
Leonard Azamfirei
{"title":"Personalized Physiological Medicine as the Future of Intensive Care Medicine.","authors":"Leonard Azamfirei","doi":"10.2478/jccm-2022-0020","DOIUrl":"https://doi.org/10.2478/jccm-2022-0020","url":null,"abstract":"","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40347788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of Critical Care Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1